← All trials
NCT00627393
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2008
- Primary completion
- Apr 1, 2013
- Completion date
- May 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 114
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- New England Research InstitutesLead sponsor
- New England Research InstitutesOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- University of IowaOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- University of MinnesotaOverall official - principal investigator
- University of WisconsinOverall official - principal investigator
- Froedtert Memorial Lutheran HospitalOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Puget Sound Blood CenterStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.